Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

human adenovirus type 5 encoding HPV-16 E6/E7 vaccine IBRX-042

A cancer vaccine composed of an adenovirus type 5 (Ad5) vector that encodes for the viral oncoproteins E6 and E7 derived from human papillomavirus serotype 16 (HPV-16; HPV16), with potential immunomodulating and antineoplastic activities. Upon administration, hAd5 encoding HPV-16 E6/E7 vaccine IBRX-042 induces expression of the HPV-16 E6/E7 proteins, which stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL)-mediated response against tumor cells expressing HPV-16 E6 and E7. Oncoproteins E6 and E7 play a key role in the development of various malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:hAd5 encoding HPV16 E6/E7 vaccine IBRX-042
hAd5-encoding HPV16 E6/E7 vaccine IBRX-042
hAd5-HPV E6.ETSD-IRES-E7.ETSD vaccine IBRX-042
Code name:IBRX 042
IBRX-042
IBRX042
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search